Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt Posted byZacks Equity Research January 7, 2022 Leave a comment on Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt Aligos Therapeutics’ (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.